{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:33:46Z","timestamp":1759451626536,"version":"build-2065373602"},"reference-count":7,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:00:00Z","timestamp":1745452800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"},{"start":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:00:00Z","timestamp":1745452800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"}],"funder":[{"name":"Universit\u00e4tsklinikum Schleswig-Holstein - Campus Kiel"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologie"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n          <jats:p>Dieser Fallbericht beschreibt den seltenen Fall einer Hodenmetastase als Erstdiagnose bei einem Nierenzellkarzinom. Der Patient stellte sich mit einer progredienten schmerzlosen Schwellung des linken Hodens vor. Nach initialem Verdacht auf einen Hodentumor wurde eine inguinale Ablatio testis durchgef\u00fchrt, die das Vorliegen eines klarzelligen Karzinoms best\u00e4tigte. Weitere Untersuchungen ergaben Hinweise auf ein prim\u00e4res Karzinom am linken Nierenunterpol, das durch eine partielle Nephrektomie entfernt wurde. Histopathologisch best\u00e4tigte sich ein klarzelliges Nierenzellkarzinom. Die Behandlung wurde durch eine adjuvante Immuntherapie mit Pembrolizumab erg\u00e4nzt. Postoperativ zeigte die bisherige Nachsorge keine Hinweise auf ein Rezidiv.<\/jats:p>","DOI":"10.1007\/s00120-025-02584-8","type":"journal-article","created":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T07:59:44Z","timestamp":1745481584000},"page":"1074-1078","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Erstdiagnose eines Nierenzellkarzinoms \u00fcber eine Hodenmetastase","First diagnosis of renal cell carcinoma via a\u00a0testicular metastasis"],"prefix":"10.1007","volume":"64","author":[{"given":"Leonhard","family":"Buck","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans Christoph","family":"von Knobloch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jakob","family":"Kohler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatih","family":"Yalcin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christiane Maria","family":"Stuhlmann-Laeisz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Severin","family":"Rodler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonas","family":"Jarczyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp","family":"Nuhn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,24]]},"reference":[{"issue":"1","key":"2584_CR1","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/1477-7525-5-34","volume":"5","author":"G Harding","year":"2007","unstructured":"Harding\u00a0G, Cella\u00a0D, Robinson\u00a0D, Mahadevia\u00a0PJ, Clark\u00a0J, Revicki\u00a0DA (2007) Symptom burden among patients with Renal Cell Carcinoma (RCC): content for a\u00a0symptom index. Health Qual Life Outcomes 5(1):34","journal-title":"Health Qual Life Outcomes"},{"issue":"17","key":"2584_CR2","doi-asserted-by":"publisher","first-page":"5636","DOI":"10.3390\/jcm12175636","volume":"12","author":"A Pliszka","year":"2023","unstructured":"Pliszka\u00a0A, Rajda\u00a0S, Wawrzyniak\u00a0A, Walocha\u00a0J, Polguj\u00a0M, Wysiadecki\u00a0G et\u00a0al (2023) Testicular metastasis from renal cell carcinoma: a\u00a0systematic review. J\u00a0Clin Med 12(17):5636","journal-title":"J Clin Med"},{"issue":"4","key":"2584_CR3","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.3892\/ol.2014.1830","volume":"7","author":"S Moriyama","year":"2014","unstructured":"Moriyama\u00a0S, Takeshita\u00a0H, Adachi\u00a0A, Arai\u00a0Y, Higuchi\u00a0S, Tokairin\u00a0T et\u00a0al (2014) Simultaneous bilateral testicular metastases from renal clear cell carcinoma: a\u00a0case report and review of the literature. Oncol Lett 7(4):1273\u20131275","journal-title":"Oncol Lett"},{"issue":"3","key":"2584_CR4","doi-asserted-by":"publisher","first-page":"128","DOI":"10.4081\/rt.2016.6471","volume":"8","author":"L Dell\u2019Atti","year":"2016","unstructured":"Dell\u2019Atti\u00a0L (2016) Unusual ultrasound presentation of testicular metastasis from renal clear cell carcinoma. Rare Tumors 8(3):128\u2013129","journal-title":"Rare Tumors"},{"key":"2584_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2020\/9394680","volume":"2020","author":"G Wang","year":"2020","unstructured":"Wang\u00a0G, Zhou\u00a0C, Villamil\u00a0CF, So\u00a0A, Yuan\u00a0R, English\u00a0JC et\u00a0al (2020) Metastatic renal cell carcinoma to the testis: a\u00a0clinicopathologic analysis of five cases. Case Rep Pathol 2020:1\u20136","journal-title":"Case Rep Pathol"},{"issue":"15","key":"2584_CR6","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1056\/NEJMoa2312695","volume":"390","author":"TK Choueiri","year":"2024","unstructured":"Choueiri\u00a0TK, Tomczak\u00a0P, Park\u00a0SH, Venugopal\u00a0B, Ferguson\u00a0T, Symeonides\u00a0SN et\u00a0al (2024) Overall survival with adjuvant pembrolizumab in renal-cell carcinoma. N\u00a0Engl J Med 390(15):1359\u20131371","journal-title":"N Engl J Med"},{"issue":"8","key":"2584_CR7","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1056\/NEJMoa2106391","volume":"385","author":"TK Choueiri","year":"2021","unstructured":"Choueiri\u00a0TK, Tomczak\u00a0P, Park\u00a0SH, Venugopal\u00a0B, Ferguson\u00a0T, Chang\u00a0YH et\u00a0al (2021) Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma. N\u00a0Engl J Med 385(8):683\u2013694","journal-title":"N Engl J Med"}],"container-title":["Die Urologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-025-02584-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00120-025-02584-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-025-02584-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T06:29:48Z","timestamp":1759386588000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00120-025-02584-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,24]]},"references-count":7,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["2584"],"URL":"https:\/\/doi.org\/10.1007\/s00120-025-02584-8","relation":{},"ISSN":["2731-7064","2731-7072"],"issn-type":[{"type":"print","value":"2731-7064"},{"type":"electronic","value":"2731-7072"}],"subject":[],"published":{"date-parts":[[2025,4,24]]},"assertion":[{"value":"21 March 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"S.\u00a0Rodler erh\u00e4lt Beratungshonorare von Merck, MSD und Novartis und besitzt Anteile an der Firma Rocketlane Medical Ventures GmbH. L.\u00a0Buck, H.C.\u00a0von Knobloch, J.\u00a0Kohler, F.\u00a0Yalcin, C.M.\u00a0Stuhlmann-Laeisz, J.\u00a0Jarczyk und P.\u00a0Nuhn geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien. F\u00fcr Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts, \u00fcber die Patient\/-innen zu identifizieren sind, liegt von ihnen und\/oder ihren gesetzlichen Vertretern\/Vertreterinnen eine schriftliche Einwilligung vor.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}